<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37258050</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>02</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>21</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1757-790X</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>May</Month><Day>31</Day></PubDate></JournalIssue><Title>BMJ case reports</Title><ISOAbbreviation>BMJ Case Rep</ISOAbbreviation></Journal><ArticleTitle>Recurrent reactive infectious mucocutaneous eruption in a male adult patient associated with <i>Mycoplasma pneumoniae</i>, SARS-CoV-2 and rhinovirus.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e254975</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bcr-2023-254975</ELocationID><Abstract><AbstractText>We present a case of a man in his early 30s who developed four episodes of reactive infectious mucocutaneous eruption (RIME), in association with different infectious pathogens.RIME is a recently implemented term to describe mucocutaneous eruptions associated with respiratory pathogens. These eruptions are characterised by predominant mucosal involvement of two or more mucous membranes and limited cutaneous involvement. The disease course and prognosis are mostly favourable, especially in recurrent episodes of RIME in the same patient. In recurrent episodes of RIME, <i>Mycoplasma pneumoniae</i> is often identified as the infectious trigger in the first episode.</AbstractText><CopyrightInformation>© BMJ Publishing Group Limited 2023. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>van Dam</LastName><ForeName>Valerie</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-1773-0187</Identifier><AffiliationInfo><Affiliation>Dermatology, Algemeen Ziekenhuis Alma campus Eeklo, Eeklo, Belgium vandamvalerie@hotmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonny</LastName><ForeName>Michiel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Dermatology, Algemeen Ziekenhuis Groeninge, Kortrijk, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Desmet</LastName><ForeName>Soetkin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Dermatology, Algemeen Ziekenhuis Alma campus Eeklo, Eeklo, Belgium.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Case Rep</MedlineTA><NlmUniqueID>101526291</NlmUniqueID><ISSNLinking>1757-790X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009177" MajorTopicYN="N">Mycoplasma pneumoniae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012229" MajorTopicYN="N">Rhinovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005076" MajorTopicYN="Y">Exanthema</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="Y">Enterovirus Infections</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Dermatology</Keyword><Keyword MajorTopicYN="N">Skin</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>5</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>1</Day><Hour>1</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>31</Day><Hour>21</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37258050</ArticleId><ArticleId IdType="pmc">PMC10254693</ArticleId><ArticleId IdType="doi">10.1136/bcr-2023-254975</ArticleId><ArticleId IdType="pii">16/5/e254975</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Canavan TN, Mathes EF, Frieden I, et al. . Mycoplasma pneumoniae-induced rash and mucositis as a syndrome distinct from Stevens-Johnson syndrome and erythema multiforme: a systematic review. J Am Acad Dermatol 2015;72:239–45. 10.1016/j.jaad.2014.06.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaad.2014.06.026</ArticleId><ArticleId IdType="pubmed">25592340</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramien ML. Reactive infectious mucocutaneous eruption: mycoplasma pneumoniae-induced rash and mucositis and other parainfectious eruptions. Clin Exp Dermatol 2021;46:420–9. 10.1111/ced.14404</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ced.14404</ArticleId><ArticleId IdType="pubmed">32918499</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryder CY, Pedersen EA, Mancuso JB. Reactive infectious mucocutaneous eruption secondary to SARS-Cov-2. JAAD Case Rep 2021;18:103–5. 10.1016/j.jdcr.2021.10.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jdcr.2021.10.007</ArticleId><ArticleId IdType="pmc">PMC8527593</ArticleId><ArticleId IdType="pubmed">34692963</ArticleId></ArticleIdList></Reference><Reference><Citation>Olson D, Abbott J, Lin C, et al. . Characterization of children with recurrent episodes of Stevens Johnson syndrome. J Pediatric Infect Dis Soc 2017;6:e140–3. 10.1093/jpids/piw085</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jpids/piw085</ArticleId><ArticleId IdType="pubmed">28339562</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazori DR, Nagarajan S, Glick SA. Recurrent reactive infectious mucocutaneous eruption (RIME): insights from a child with three episodes. Pediatr Dermatol 2020;37:545–7. 10.1111/pde.14142</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/pde.14142</ArticleId><ArticleId IdType="pubmed">32172537</ArticleId></ArticleIdList></Reference><Reference><Citation>Maredia H, Eseonu A, Grossberg AL, et al. . Recurrent mycoplasma pneumoniae-associated reactive infectious mucocutaneous eruption responsive to systemic steroids: a case series. JAAD Case Reports 2021;11:139–43. 10.1016/j.jdcr.2021.03.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jdcr.2021.03.009</ArticleId><ArticleId IdType="pmc">PMC8100349</ArticleId><ArticleId IdType="pubmed">33997214</ArticleId></ArticleIdList></Reference><Reference><Citation>Song A, Nicholson C, Maguiness S. Recurrent reactive infectious mucocutaneous eruption (RIME) in two adolescents triggered by several distinct pathogens including SARS-Cov-2 and influenza A. Pediatr Dermatol 2021;38:1222–5. 10.1111/pde.14780</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/pde.14780</ArticleId><ArticleId IdType="pmc">PMC8646723</ArticleId><ArticleId IdType="pubmed">34515364</ArticleId></ArticleIdList></Reference><Reference><Citation>Liakos W, Xu A, Finelt N. Clinical features of recurrent mycoplasma pneumoniae-induced rash and mucositis. Pediatr Dermatol 2021;38:154–8. 10.1111/pde.14472</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/pde.14472</ArticleId><ArticleId IdType="pubmed">33247484</ArticleId></ArticleIdList></Reference><Reference><Citation>Daubeney PE, Scopes JW. Recurrent Stevens-Johnson syndrome. J R Soc Med 1991;84:168. 10.1177/014107689108400319</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/014107689108400319</ArticleId><ArticleId IdType="pmc">PMC1293141</ArticleId><ArticleId IdType="pubmed">2013900</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn-Dall’Magro A, Zamboni E, Fontana T, et al. . Low-level laser therapy in the management of oral mucositis induced by radiotherapy: a randomized double-blind clinical trial. J Contemp Dent Pract 2022;23:31–6.</Citation><ArticleIdList><ArticleId IdType="pubmed">35656654</ArticleId></ArticleIdList></Reference><Reference><Citation>Legouté F, Bensadoun R-J, Seegers V, et al. . Low-level laser therapy in treatment of Chemoradiotherapy-induced mucositis in head and neck cancer: results of a randomised, triple blind, multicentre phase III trial. Radiat Oncol 2019;14:83. 10.1186/s13014-019-1292-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13014-019-1292-2</ArticleId><ArticleId IdType="pmc">PMC6530019</ArticleId><ArticleId IdType="pubmed">31118057</ArticleId></ArticleIdList></Reference><Reference><Citation>Yousef M, Mansouri P, Partovikia M, et al. . The effect of low level laser therapy on Pemphigus Vulgaris lesions: a pilot study. J Lasers Med Sci 2017;8:177–80. 10.15171/jlms.2017.32</Citation><ArticleIdList><ArticleId IdType="doi">10.15171/jlms.2017.32</ArticleId><ArticleId IdType="pmc">PMC5642165</ArticleId><ArticleId IdType="pubmed">29071023</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>